MEN 10710 is a new synthetic
distamycin derivative possessing four
pyrrole rings and a bis-(2-chloroethyl)aminophenyl moiety linked to the oligopyrrole backbone by a flexible butanamido chain. Its
biological properties have been investigated in comparison with the structurally related compound,
tallimustine (FCE24517), and the classical
alkylating agent,
melphalan (
L-PAM). Cytotoxic potency of
MEN 10710 was increased from 10- to 100-fold, as compared to
tallimustine or
L-PAM in murine L1210, human LoVo and MCF7 tumor cell lines.
MEN 10710 was still active against L1210/
L-PAM leukemic cells, while a partial cross-resistance was observed in LoVo/DX and in MCF7/DX cells selected for resistance to
doxorubicin and expressing a MDR phenotype. Treatment with
verapamil (VRP) reduced the resistance to
tallimustine, but not to
MEN 10710, in MCF7/DX cells. The cytotoxic effects reflect in vivo antitumor potency and toxicity in the treatment of human
tumor xenografts.
MEN 10710 was more effective in A2780/DDP, an ovarian
carcinoma selected for resistance to
cisplatin. On the other hand, the IC30 for inhibiting murine granulocyte/macrophage colony formation was 50 times higher for
MEN 10710 than for
tallimustine, suggesting a lower myelotoxic potential. In conclusion, the particular
biological profile of
MEN 10710 characterized by a marked cytotoxic potency, an interesting antitumor efficacy and a reduced in vitro myelosuppressive action may represent a further improvement in the rational design of a novel
distamycin-related alkylating compound.